Abstract
Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.
Keywords:
bortezomib; dexamethasone; lenalidomide; myeloma.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Antineoplastic Agents* / administration & dosage
-
Antineoplastic Agents* / therapeutic use
-
Bortezomib* / administration & dosage
-
Bortezomib* / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Dexamethasone* / administration & dosage
-
Dexamethasone* / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use
-
Lenalidomide* / administration & dosage
-
Lenalidomide* / therapeutic use
-
Male
-
Multicenter Studies as Topic
-
Multiple Myeloma* / drug therapy
Substances
-
Anti-Inflammatory Agents
-
Antineoplastic Agents
-
Bortezomib
-
Dexamethasone
-
Immunologic Factors
-
Lenalidomide